Literature DB >> 7829408

In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation.

T Ichimiya1, T Yamasaki, M Nasu.   

Abstract

The in-vitro effects of ten antimicrobial agents on the biofilm formation of Pseudomonas aeruginosa were investigated. The production of alginic acid by mucoid P. aeruginosa cells cultured in agar media with sub-MICs of antimicrobial agents was quantified by high-performance liquid chromatography. Alginic acid production was inhibited by 1/4 MIC of minocycline (P < 0.002) and tobramycin (P < 0.02), and by 1/256-1/1/64 MIC of macrolides (erythromycin, clarithromycin, roxithromycin, and rokitamycin) and clindamycin (P < 0.02), compared with drug-free controls. Piperacillin, ceftazidime, and ofloxacin did not inhibit alginic acid production. The production of exopolysaccharide by non-mucoid P. aeruginosa cells grown on silicone plates in sub-MICs of antimicrobial agents was determined by quantitative tryptophan assay. Exopolysaccharide production was inhibited by 1/16 MIC of macrolides and clindamycin, but not by other antimicrobial agents. Electron microscopy showed that biofilm formation by mucoid and non-mucoid type P. aeruginosa strains was inhibited by sub-MICs of erythromycin and correlated with the in-vitro production of alginic acid and exopolysaccharide. These results suggest that sub-MICs of macrolides and clindamycin suppress biofilm formation by P. aeruginosa and that intractable chronic respiratory tract infections due to P. aeruginosa might be prevented.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7829408     DOI: 10.1093/jac/34.3.331

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Lung infections. 3. Pseudomonas aeruginosa and other related species.

Authors:  R Wilson; R B Dowling
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

2.  Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin.

Authors:  K Tateda; Y Ishii; T Matsumoto; N Furuya; M Nagashima; T Matsunaga; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Rearrangement of a large novel Pseudomonas aeruginosa gene island in strains isolated from a patient developing ventilator-associated pneumonia.

Authors:  G Singh; R Srinivasan; J Cheng; Z Peng; K Fujimura; M S Baek; A R Panzer; S G Tringe; F Chen; R Sorek; L Weng; J Bristow; J P Wiener-Kronish; S V Lynch
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

4.  Inhibition of Pseudomonas aeruginosa alginate expression by subinhibitory concentrations of antibiotics.

Authors:  V Majtán; D Hybenová
Journal:  Folia Microbiol (Praha)       Date:  1996       Impact factor: 2.099

5.  Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.

Authors:  Lisa Saiman; Yunhua Chen; Pablo San Gabriel; Charles Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

6.  Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.

Authors:  Juliet E Foweraker; Christian R Laughton; Derek F Brown; Diana Bilton
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

Review 7.  Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

Authors:  Susan M Cheer; John Waugh; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm.

Authors:  Larissa Lutz; Dariane Castro Pereira; Rodrigo Minuto Paiva; Alexandre Prehn Zavascki; Afonso Luis Barth
Journal:  BMC Microbiol       Date:  2012-09-08       Impact factor: 3.605

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.